Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing

Foley, Georgea R.; Marthick, James R.; Ostrander, Elaine A.; Stanford, Janet L.; Dickinson, Joanne L.; FitzGerald, Liesel M.

doi:10.1016/j.ejca.2022.11.034

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in this gene have been associated with an increased risk of prostate cancer. Another gene known to play a role in prostate cancer susceptibility is the BRCA1 and BRCA2 genes [52]. These genes are commonly associated with breast and ovarian cancer, but have also been linked to an increased risk of prostate cancer.…”

Section: Prostate Cancer Susceptibility and Armentioning

confidence: 99%

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer

Zakari,

Ekenwaneze,

Amadi

et al. 2023

Preprint

View full text Add to dashboard Cite

Prostate cancer (PCa) is a major cause of cancer-related mortality worldwide, with a rising incidence observed over the years. The androgen receptor (AR) signaling pathway plays a pivotal role in male development and maintaining masculine characteristics. Dysregulation of AR signaling in prostate cancer can lead to disease progression and resistance to standard therapies. Understanding the intricate regulation and function of AR in both healthy and diseased states is crucial for developing effective treatment strategies. This review comprehensively explores the role of androgen receptors in prostate cancer susceptibility, disease progression, and treatment response by analyzing recent literature. An extensive search of peer-reviewed publications in major databases, including PubMed, Scopus, and Web of Science, was conducted using specific keywords related to androgen receptor, prostate cancer, disease progression, and treatment resistance. Relevant conference abstracts and clinical trial reports were also included. The review presents an overview of the role of androgen receptors in prostate cancer initiation, progression, and treatment resistance. It highlights emerging biomarkers associated with AR signaling dysregulation and their potential utility for early detection and personalized treatment approaches. Additionally, recent advances in targeting the AR pathway for novel therapeutic strategies to improve patient outcomes and overcome treatment resistance in advanced prostate cancer are discussed. The findings contribute to a comprehensive understanding of the AR signaling pathway in prostate cancer and offer insights into its multifaceted role in disease development and treatment response. They may pave the way for innovative therapeutic interventions and precision medicine approaches based on specific AR signaling profiles, enhancing patient care and reducing the burden of this lethal disease.

show abstract

Section: Prostate Cancer Susceptibility and Armentioning

confidence: 99%

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer

Zakari,

Ekenwaneze,

Amadi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Role of ethnic and genetic factors in the development of prostate cancer (Review)

Saliev,

Akhmad,

Altynbekova

et al. 2024

World Acad Sci J

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common malignancies worldwide, particularly affecting older males. Genetic and ethnic factors play a critical role in the development, progression and mortality rate associated with PCa. The present review focuses on the influence of race and genetic predisposition, particularly the mutations in BRCA1 and BRCA2 genes, which markedly increase the risk of developing aggressive forms of PCa. African American males, in particular, are more susceptible to PCa, with a higher incidence of aggressive disease compared to other ethnic groups. These genetic disparities highlight the importance of targeted genetic screening and personalized healthcare strategies to mitigate the risk of developing PCa in vulnerable populations. The key conclusions from the present review emphasize the necessity of integrating genetic testing into routine PCa screening protocols, particularly for high-risk groups, such as males with a family history of PCa or those of African descent. Personalized treatment options, such as the use of PARP inhibitors for patients with BRCA mutations, present a promising approach to improving the outcomes of patients with PCa. The present review calls for further research into the interactions between genetic and environmental factors in PCa and the development of tailored intervention programs to reduce incidence and mortality among high-risk populations. Expanding access to genetic counselling and testing services is crucial to improving early detection and preventive care. Contents1. Introduction 2. Literature search strategies 3. Influence of race on the occurrence of prostate cancer 4. Hereditary risk factors for the development of prostate cancer 5. Mutations of the BRCA1 and BRCA2 genes as a risk factor for developing prostate cancer 6. Synopsis 7. Conclusions and future perspectives

show abstract

Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing

Cited by 2 publications

References 7 publications

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer

Role of ethnic and genetic factors in the development of prostate cancer (Review)

Contact Info

Product

Resources

About